SCHEDULE 1 - MBPRG

Medulloblastoma Preclinical Ribociclib and Gemcitabine (MBPRG) Data Set Publications Policy

The MBPRG dataset comprises medulloblastoma group 3 (G3 MB) patient-derived-orthotopic xenografts (PDOX) and mouse G3 MB tumor models. Both human (PDOX) and mouse tumor models were treated with either ribociclib (CDK4/6 inhibitor), gemcitabine (metabolic inhibitor of DNA synthesis), or the combination of these two drugs in comparison to control (vehicle). The key objective of this dataset is to evaluate the impact of this treatment and identify perturbation of gene expression/pathways at the transcriptional level in G3 MB.

The MBPRG Data Access Committee anticipates that data generated from the project will be used by other researchers (scientists who are employed by, or a student enrolled at or legitimately affiliated with, an academic, non-profit, or government institution, or a commercial company) to develop new analytical methods, validate results, and identify additional genetic variatons, alterations, associations, and correlations in the data.

Authors who use data from the project must acknowledge the MBPRG using the following wording "This study makes use of data generated by the Medulloblastoma Preclinical Ribociclib and Gemcitabine Data Set of St. Jude Children's Research Hospital" and cite the primary MBPRG publication (see end of schedule).

Users should note that the MBPRG Data Access Committee bears no responsibility for the further analysis or interpretation of these data, over and above that published by the MBPRG.

Primary MBPRG publication:
Pribnnow A, Jonchere B, Liu J et al. Combination of ribociclib and gemcitabine for the treatment of medulloblastoma. *Molecular Cancer Theraputics*. (Manuscript accepted).